What to watch with CYP2D6 and Wechseljahre?

CYP2D6 is a key drug-metabolizing enzyme that processes many medications commonly used during menopause, such as certain antidepressants (e.g., paroxetine), beta-blockers (e.g., metoprolol), and tamoxifen. Genetic variants can lead to poor or ultrarapid metabolism, potentially altering drug efficacy and side effect risk. During menopause, this means standard doses may not work as expected or may cause stronger side effects. However, the provided context contains no specific data on CYP2D6 or menopause. The evidence for routine genetic testing to guide menopause therapy is moderate, based on pharmacogenetic guidelines (e.g., CPIC, DPWG), not on the sources given here. A consumer DNA test alone is insufficient for clinical decisions. Important: Never adjust or stop medications on your own. Consult a healthcare provider who can consider pharmacogenetic testing if appropriate. Evidence is rated as 'practice' because clinical guidelines exist, but application in the consumer setting remains uncertain.